for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.O

Latest Trade

329.63USD

Change

56.24(+20.57%)

Volume

35,901,209

Today's Range

313.00

 - 

350.15

52 Week Range

102.66

 - 

497.49

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
273.39
Open
319.34
Volume
35,901,209
3M AVG Volume
271.82
Today's High
350.15
Today's Low
313.00
52 Week High
497.49
52 Week Low
102.66
Shares Out (MIL)
405.45
Market Cap (MIL)
133,648.30
Forward P/E
12.79
Dividend (Yield %)
--

Next Event

Moderna Inc at Nasdaq Investor Conference (Virtual)

Latest Developments

More

EMA Publishes Assessment Report Supporting Recommendations For Spikevax Booster Dose

U.S. FDA Said To Be Ready To Endorse Pfizer And Moderna Boosters At Once- Politico

Moderna Files For Authorization Of Its COVID-19 Vaccine With Health Canada To Include Children Ages 6-11 Years

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Moderna Inc

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics.

Industry

Biotechnology & Drugs

Contact Info

200 Technology Sq

Cambridge, MA

02139-3578

United States

+1.617.7146500

https://www.modernatx.com/

Executive Leadership

Noubar B. Afeyan

Non-Executive Independent Chairman of the Board, Co-Founder

Stephen Hoge

President

Stephane Bancel

Chief Executive Officer, Director

David Meline

Chief Financial Officer

Tracey Franklin

Chief Human Resources Officer

Key Stats

2.67 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.8K

2021(E)

17.4K
EPS (USD)

2018

-4.950

2019

-1.550

2020

-1.960

2021(E)

25.765
Price To Earnings (TTM)
20.24
Price To Sales (TTM)
11.30
Price To Book (MRQ)
13.19
Price To Cash Flow (TTM)
18.50
Total Debt To Equity (MRQ)
4.50
LT Debt To Equity (MRQ)
2.35
Return on Investment (TTM)
99.86
Return on Equity (TTM)
55.22

Latest News

Latest News

Swiss strike deal for COVAX to get 1 million Moderna doses more quickly

Switzerland has become the first country to swap places in the supply queue for COVID-19 vaccines, allowing 1 million doses of the Moderna shot to go first to the COVAX dose-sharing programme, the GAVI vaccine alliance said on Wednesday.

Germany promotes 'Rolls-Royce' Moderna shot to meet demand for COVID boosters

Germany will promote Moderna for Germans seeking booster shots as high demand for the BioNTech/Pfizer vaccine risks depleting stocks and derailing efforts to tame a fourth wave of the pandemic, Health Minister Jens Spahn said on Monday.

Germany has enough mRNA shots to meet vaccine demand- Spahn

Health Minister Jens Spahn sought to allay concerns on Monday that Germany was running out of BioNTech/Pfizer vaccine shots, saying that enough supplemental Moderna doses were available to meet demand during the remainder of the year.

U.S. expands COVID-19 booster eligibility to all adults

(This November 19 story was corrected to say 60% of Americans are fully vaccinated in last paragraph)

U.S. CDC advisers embrace COVID-19 booster shots for all adults

Advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Friday voted to recommend expanding eligibility of booster doses of the Pfizer /BioNTech and Moderna COVID-19 vaccines to all adults.

FDA authorizes Moderna vaccine booster shots for all adults

Moderna Inc said on Friday the U.S. Food and Drug Administration has extended the emergency use authorization of a booster dose of its COVID-19 vaccine to all adults aged 18 and older.

Moderna seeks U.S. authorization of COVID-19 booster shots for all adults

Moderna Inc said on Wednesday it had applied with the U.S. Food and Drug Administration for authorization of its COVID-19 booster vaccine for all adults aged 18 and older.

Moderna applies for U.S. authorization of COVID-19 vaccine boosters for adults

Moderna Inc said on Wednesday it had applied with the U.S. Food and Drug Administration for authorization of its COVID-19 booster vaccine for all adults aged 18 and older . (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila)

Moderna says EU to donate over 70 million doses of its COVID-19 vaccine

Moderna Inc said on Tuesday it signed an agreement that enables European Union and European Economic Area countries to donate over 70 million doses of its COVID-19 vaccine to the COVAX vaccine sharing scheme for low-and-middle income countries.

Moderna offers COVID-19 shot at $7 to African Union - Africa CDC head

Moderna Inc has offered to sell its COVID-19 vaccines to the African Union at $7 a shot, head of the Africa Centres for Disease Control John Nkengasong said on Thursday, half the price paid by the United States earlier in the year.

Moderna offers COVID-19 shot at $7 to African Union - Africa CDC head

Moderna Inc has offered to sell its COVID-19 vaccines to the African Union at $7 a shot, head of the Africa Centres for Disease Control John Nkengasong said on Thursday.

Moderna applies for COVID-19 booster shot approval from Japan's health ministry -NHK

Moderna Inc applied for approval from Japan's health ministry on Wednesday to use their COVID-19 vaccines for booster shots, broadcaster NHK reported on Thursday.

Moderna COVID-19 vaccine patent dispute headed to court, U.S. NIH head says

U.S. National Institutes of Health scientists played "a major role" in developing Moderna Inc's COVID-19 vaccine and the agency intends to defend its claim as co-owner of patents on the shot, NIH Director Dr. Francis Collins told Reuters on Wednesday.

Moderna COVID-19 vaccine patent dispute headed to court -U.S. NIH head says

U.S. National Institutes of Health scientists played "a major role" in developing Moderna Inc's COVID-19 vaccine and the agency intends to defend its claim as co-owner of patents on the shot, NIH Director Dr. Francis Collins told Reuters on Wednesday.

Germany recommends only Biontech/Pfizer vaccine for under-30s

People aged under 30 in Germany should only receive the Biontech/Pfizer COVID-19 vaccine as it causes fewer heart inflammations in younger people than the Moderna shot, an advisory committee said on Wednesday.

CORRECTED-UPDATE 1-Germany recommends only Biontech/Pfizer vaccine for people under 30

Germany's vaccine advisory committee recommends people under 30 be vaccinated only with the Biontech/Pfizer COVID-19 vaccine as it showed a lower number of heart inflammations in younger people than the Moderna vaccination, it said on Wednesday.

EU to decide on Moderna's COVID-19 shot for younger kids in two months

The European Union's drug regulator expects to decide in about two months on whether to allow the use of Moderna's COVID-19 vaccine in children aged six to 11 years, it said on Wednesday, after the U.S. drugmaker sought approval.

French health authority advises against Moderna COVID-19 vaccine for under 30s

France's public health authority has recommended people under 30 be given Pfizer's Comirnaty COVID-19 vaccine when available instead of Moderna Inc's Spikevax jab, which carried comparatively higher risks of heart-related problems.

Moderna seeks EU authorization for COVID-19 vaccine in young children

Moderna Inc on Tuesday applied for European authorization of its COVID-19 vaccine in children aged 6-11 years, weeks after it delayed a similar filing with U.S. regulators.

Moderna seeks EU authorization for COVID-19 vaccine in young kids

Moderna Inc said on Tuesday it has submitted for a variation to the conditional marketing authorization with the European Medicines Agency for the evaluation of its COVID-19 vaccine's use in children in the age-group of 6-11 years. (Reporting by Manojna Maddipatla in Bengaluru...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up